ASH 2023 | Acalabrutinib plus rituximab for treating anti-MAG mediated IgM peripheral neuropathy in WM
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses a Phase II trial (NCT05065554) investigating the combination of acalabrutinib and rituximab in the treatment of anti-myelin associated glycoprotein (MAG) mediated IgM peripheral neuropathy in patients with Waldenström’s macroglobulinemia (WM). This combination regimen resulted in improvements in neuropathy in 75% of the patients for which data is currently available. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Pharmacyclics, BeiGene, Cellectar, AstraZeneca, Mustang Bio, Kite, Loxo, Abbvie
Research Funding: Pharmacyclics, BeiGene, Cellectar, AstraZeneca, Loxo, Abbvie
